Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | LCLAT1 | Q6UWP7 | 3/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 3/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516696 | 1.00 | LDHA (0.42) | LDHAEIF4ELCLAT1P2RX7FEN1 | |
| SCHEMBL24478734 | 0.88 | NPC1 (0.38) | LDHAP2RX7MKNK2GABRA5NPC1 | |
| SCHEMBL30516692 | 0.88 | NPC1 (0.38) | LDHAP2RX7MKNK2GABRA5NPC1 | |
| SCHEMBL24478656 | 0.72 | KDM4E (0.39) | LCLAT1 | |
| SCHEMBL30516694 | 0.72 | KDM4E (0.39) | LCLAT1 | |
| SCHEMBL20522192 | 0.70 | PKM (0.46) | LCLAT1MKNK2KEAP1 | |
| SCHEMBL24478613 | 0.70 | GRM5 (0.37) | P2RX7GRM5 | |
| SCHEMBL30516697 | 0.70 | GRM5 (0.37) | P2RX7GRM5 | |
| SCHEMBL29631164 | 0.70 | GRM5 (0.34) | GRM5 | |
| SCHEMBL24478743 | 0.69 | PARP1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| CN-116601149-A | Aminoquinazoline derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | LDHA 4586/4885EIF4E 2513/4885LCLAT1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.